Results 121 to 130 of about 27,075 (224)
SPHK1 enhances olaparib resistance in ovarian cancer through the NFκB/NRF2/ferroptosis pathway
Cell Death DiscoveryPARPis resistance is a challenge in the treatment of ovarian cancer. To investigate the potential mechanism involved in olaparib resistance of ovarian cancer, high-throughput sequencing was performed on olaparib-resistant SKOV3 cell line named SK/Ola ...
Kai Teng +4 more
doaj +1 more source
Molecular Oncology, Volume 20, Issue 9, Page 2135-2162, September 2026.The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant +7 more
wiley +1 more source
Advanced Science, Volume 13, Issue 50, 7 September 2026.This study introduces a biomimetic “nanofusion” platform that integrates the biostability of threose nucleic acids (TNA) with homotypic cell‐membrane cloaking to combat drug‐resistant TNBC. By leveraging a non‐canonical membrane‐fusion pathway for direct cytosolic delivery, the platform bypasses endosomal sequestration. To achieve potent AKT2 silencing
Wei Zheng +7 more
wiley +1 more source
Olaparib elicits an increase in TRAIL receptor 2 (DR5) expression in GBM cells.
, 2014 A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B–D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (
Peter Canoll (220255) +9 more
core +1 more source
Versatile Detection of Cellular Protein via Fluorescence Anisotropy
Advanced Science, Volume 13, Issue 51, 14 September 2026.Cell Lysate Fluorescence Anisotropy (CFAST) utilizes long lifetime dye‐labeled nanobodies for rapid protein quantification in minimally purified, complex cell lysate. When coupled with cellular thermal shift, CFAST allows high‐throughput detection of endogenous protein‐small molecule engagement, facilitating the discovery of novel binders for ...
Qing Tang +12 more
wiley +1 more source
Cancer Cell InternationalPurpose We tested whether the PARP inhibitor, Olaparib, can effectively enhance radiosensitivity while inhibiting OSCC growth and metastasis in vitro and in vivo. Patient samples were used for survival validation.
Chih-Chia Yu +12 more
doaj +1 more source
Advanced Science, Volume 13, Issue 53, 24 September 2026.This study shows that a PARP inhibitor combined with anlotinib, administered as bridging therapy, preconditions the tumor microenvironment to enhance the infiltration and antitumor activity of subsequently infused CAR‐T cells across preclinical ovarian cancer models, supporting bridging therapy as a promising strategy to address limited CAR‐T cell ...
Huayi Li +20 more
wiley +1 more source
PD‐L1 in Ovarian Cancer: Immune Evasion, Tumor‐Intrinsic Signaling, and Chemoresistance
Cancer Medicine, Volume 15, Issue 9, September 2026.The “Dual Shield” model of PD‐L1 in ovarian cancer. On the outside, PD‐L1 engages PD‐1 to inactivate T cells and drive immune evasion (immune shield). Inside the tumor cell, PD‐L1 activates AKT–mTOR, enhances DNA repair, rewires metabolism, supports autophagy, and enforces stemness programs—collectively creating a chemoresistance shield.
Zhiyang Xu +3 more
wiley +1 more source
PharmaceuticalsBackground: Ovarian cancer remains one of the leading causes of cancer-related mortality among women and constitutes a major unmet medical need. A common treatment-limiting factor for ovarian cancer patients is resistance to Poly(ADP-ribose) polymerase ...
Szymon W. Kmiecik +5 more
doaj +1 more source
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells [PDF]
SIGNIFICANCE: Olaparib, a PARP inhibitor, is effective against various cancers, including prostate cancer. However, resistance to olaparib poses a significant challenge.
Sharifi, Masuda +11 more
core +1 more source